Transcatheter aortic valve replacement (TAVR) for high-risk, older patients with severe aortic stenosis is now standard therapy. Its expanded use in other patient populations – including younger patients with lower risk – has been tested in several randomized trials.

Many now think that TAVR should be a universal therapeutic first choice – but do the data really support this stance?

This month Cardiology takes a look at the evidence for determining which patients are best suited for TAVR, based on what the data show, and which patients are perhaps still better served by surgical aortic valve replacement (SAVR).

Clinical Topics: Cardiac Surgery, Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Aortic Surgery, Cardiac Surgery and VHD, Interventions and Structural Heart Disease

Keywords: ACC Publications, Cardiology Magazine, Transcatheter Aortic Valve Replacement, Aortic Valve, Aortic Valve Stenosis, Heart Valve Prosthesis, Risk, Cardiology, Reference Standards

< Back to Listings